Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002313558 | SCV000848641 | uncertain significance | Inborn genetic diseases | 2016-12-15 | criteria provided, single submitter | clinical testing | The p.R2240Q variant (also known as c.6719G>A), located in coding exon 46 of the CACNA1A gene, results from a G to A substitution at nucleotide position 6719. The arginine at codon 2240 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001868349 | SCV002205572 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2022-12-13 | criteria provided, single submitter | clinical testing | |
Ce |
RCV004569408 | SCV005051048 | uncertain significance | not provided | 2024-05-01 | criteria provided, single submitter | clinical testing | CACNA1A: PP3 |